Dabrafenib Plus Trametinib in Elderly Patients With BRAF V600–Mutant Advanced Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Safety of combining dabrafenib plus trametinib in elderly BRAF V600 mutation-positive advanced melanoma patients: real-world data analysis of Spanish patients (ELDERLYMEL)
Melanoma Res. 2022 Jun 27;[EPub Ahead of Print], I González-Barrallo, VE Castellón Rubio, J Medina, S España, K Mujika, M Majem, C Aguado, MÁ Cabrera Suárez, I Palacio, L Osterloh, A Martínez-Fernández, A García-CastañoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.